Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

Journal of Clinical Lipidology

Year: 2012  |  Volume: 6  |  Issue: 3  |  Page No.: 253 - 254

Changes in Lipoprotein-associated Phospholipase A2 with Ezetimibe/Simvastatin Co-administered with ER Niacin in Type II Hyperlipidemia

Ngoc-Anh Le, Monica Farkas-Epperson, Ran Jin, Andrew M. Tershakovec, David R. Neff, Robert Wolfert, Joanne E. Tomassini and Peter Wilson

Abstract

High levels of lipoprotein-associated phospholipase A2 (LpPLA2) are associated with increased risk of cardiovascular disease. LpPLA2 is an inflammatory enzyme marker and is less prone to effects of systemic infection as are other inflammatory markers such as C-reactive protein (hsCRP). In a previously reported study, co-administration of ezetimibe/simvastatin (E/S) 10/20 mg with extended-release niacin up to 2 g/day (N) reduced low-density lipoprotein cholesterol and increased high-density lipoprotein cholesterol levels significantly more than E/S and N alone in patients with type IIa/IIb hyperlipidemia (T2HLP) during 24 weeks.

View Fulltext